FDA approves Empagliflozin [Jardiance], a SGLT2 inhibitor, to treat type 2 diabetes
August 1, 2014 – The U.S. Food and Drug Administration today approved Jardiance (empagliflozin) tablets as an addition to diet and exercise to improve glycemic control in adults with type 2 diabetes. Type 2 diabetes affects approximately 26 million people …
FDA approves Empagliflozin [Jardiance], a SGLT2 inhibitor, to treat type 2 diabetes Read more »